Innovating Works

Fight-nCoV

Financiado
FIGHTING OFF CORONAVIRUS SARS CoV 2 WITH BROAD SPECTRUM ANTIVIRALS ESTABLISHI...
FIGHTING OFF CORONAVIRUS SARS CoV 2 WITH BROAD SPECTRUM ANTIVIRALS ESTABLISHING ANIMAL VIRAL CHALLENGE MODEL Project coordinator: Professor Anna-Lena Spetz, MD, PhD, Stockholm University, Sweden Objectives of proposal: Our consortium Fight-nCoV will accelerate preclinical development of new broad-spectrum antivirals for inhalation, buil... Project coordinator: Professor Anna-Lena Spetz, MD, PhD, Stockholm University, Sweden Objectives of proposal: Our consortium Fight-nCoV will accelerate preclinical development of new broad-spectrum antivirals for inhalation, building on breath-taking ongoing research. We will determine and characterize the antiviral activity and safety of three viral entry inhibitors (oligonucleotide, Macro-I, tweezer) against SARS-CoV-2 in vitro and in vivo. To enable this, we will build capacity for evaluation of antiviral efficacy against SARS-CoV-2 in vitro using viral pseudotypes and wild-type SARS-CoV-2 as well as in vivo in non-human primates. Safety studies will be performed according to OECD GLP guidelines. Expected results: We will establish a SARS-CoV-2 spike pseudotype system allowing a standardized high throughput evaluation of the antiviral activity of candidate drugs. We will have determined the antiviral efficacy of three novel broad-spectrum viral entry inhibitors: oligonucleotide, macromolecular polymers, and molecular tweezers. We will also build capacity for innovation and preclinical evaluation of our broad-spectrum antivirals and vaccines against SARS-CoV-2 by establishing a macaque challenge model. Fight-nCoV will provide efficacy data of our drug candidates given intranasally in non-human primates challenged with SARS-CoV-2, enable an early and valuable outcome for stakeholders and the civil society. Timeline of proposal: Ongoing-30 months Key partners: Roger Le Grand, Director animal facility, CEA, France; Urban Höglund, CEO Adlego Biomedical, Sweden; Jan Münch, Professor in Molecular Virology, UULM, Germany; Alexander Zelikin, Associate Professor, formulation expert, AU, Denmark; and Thomas Schrader, Professor of Chemistry, UDE, Germany. ver más
30/09/2022
STOCKHOLMS UNIVERS...
3M€
Perfil tecnológico estimado
Duración del proyecto: 29 meses Fecha Inicio: 2020-04-06
Fecha Fin: 2022-09-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2022-09-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
SC1-PHE-CORONAVIRUS-2020: Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic
Cerrada hace 4 años
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
STOCKHOLMS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.